Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - CAPRICOR THERAPEUTICS, INC. | v465311_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - CAPRICOR THERAPEUTICS, INC. | v465311_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - CAPRICOR THERAPEUTICS, INC. | v465311_ex31-1.htm |
| 10-Q - 10-Q - CAPRICOR THERAPEUTICS, INC. | v465311_10q.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Leland Gershell, M.D., Ph.D., the Principal Financial Officer of Capricor Therapeutics, Inc. (the “Company”), hereby certifies, to his knowledge, that:
(1) the Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.
Date: May 15, 2017
| /s/ Leland Gershell, M.D., Ph.D. | |
| Name: Leland Gershell, M.D., Ph.D. | |
| Title: Chief Financial Officer and Principal Financial Officer |